Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2014 | Pages:
309 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2014', provides an overview of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Overview 9 Therapeutics Development 10 Pipeline Products for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Overview 10 Pipeline Products for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Comparative Analysis 11 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics under Development by Companies 12 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics under Investigation by Universities/Institutes 16 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Products Glance 18 Late Stage Products 18 Clinical Stage Products 19 Early Stage Products 20 Unknown Stage Products 21 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Products under Development by Companies 22 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Products under Investigation by Universities/Institutes 25 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Companies Involved in Therapeutics Development 26 Bristol-Myers Squibb Company 26 Boehringer Ingelheim GmbH 27 GlaxoSmithKline plc 28 Gamida Cell Ltd. 29 BioLineRx, Ltd. 30 Piramal Enterprises Limited 31 Nanotherapeutics, Inc. 32 Bio-Path Holdings, Inc. 33 Novartis AG 34 Ono Pharmaceutical Co., Ltd. 35 Pfizer Inc. 36 Celgene Corporation 37 Incyte Corporation 38 Ariad Pharmaceuticals, Inc. 39 JW Pharmaceutical Corporation 40 Ilyang Pharmaceutical Co., Ltd 41 Jiangsu Hengrui Medicine Co., Ltd. 42 Threshold Pharmaceuticals, Inc. 43 Synta Pharmaceuticals Corp. 44 Natco Pharma Limited 45 Hybrigenics S.A. 46 SymBio Pharmaceuticals Limited 47 Nerviano Medical Sciences 48 Constellation Pharmaceuticals, Inc. 49 Deciphera Pharmaceuticals, LLC 50 Stemline Therapeutics, Inc. 51 Onconova Therapeutics, Inc. 52 Mirna Therapeutics, Inc. 53 KaloBios Pharmaceuticals, Inc. 54 AB Science 55 Aprea AB 56 PharmaEssentia Corporation 57 Targa Therapeutics Corp. 58 Otsuka Holdings Co., Ltd. 59 Shenogen Pharma Group Ltd. 60 BerGenBio AS 61 Karyopharm Therapeutics, Inc. 62 Cantargia AB 63 AbbVie Inc. 64 Biogenomics Limited 65 Galileo Research s.r.l. 66 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics Assessment 67 Assessment by Monotherapy Products 67 Assessment by Target 68 Assessment by Mechanism of Action 72 Assessment by Route of Administration 76 Assessment by Molecule Type 78 Drug Profiles 81 bosutinib - Drug Profile 81 ponatinib - Drug Profile 83 StemEx - Drug Profile 85 bosutinib - Drug Profile 86 radotinib - Drug Profile 88 ponatinib - Drug Profile 90 BMS-833923 - Drug Profile 92 Triapine - Drug Profile 94 danusertib - Drug Profile 96 Cell Therapy for Oncology and Infectious Disease - Drug Profile 98 NRCAN-019 - Drug Profile 99 TALL-104 - Drug Profile 101 HHGV-678 - Drug Profile 103 BL-8040 - Drug Profile 104 Vaccine to Target WT1 for CML and AML - Drug Profile 106 trametinib dimethyl sulfoxide - Drug Profile 107 binimetinib - Drug Profile 110 ruxolitinib phosphate - Drug Profile 114 SL-401 - Drug Profile 118 rigosertib sodium - Drug Profile 120 KB-004 - Drug Profile 124 APR-246 - Drug Profile 126 Gene Therapy for AML and CML - Drug Profile 127 PRI-724 - Drug Profile 128 dianhydrogalactitol - Drug Profile 130 Minor Histocompatibility Antigen - Drug Profile 132 Cell Therapy to Target WT1 for Cancer - Drug Profile 133 Cell Therapy for Hematological Malignancies - Drug Profile 134 volasertib - Drug Profile 135 azacitidine - Drug Profile 137 ganetespib - Drug Profile 140 TH-302 - Drug Profile 144 peginterferon alfa-2b - Drug Profile 151 Cell Therapy to Target GM-CSF for Oncology - Drug Profile 153 HuM-195/rGel - Drug Profile 154 erismodegib - Drug Profile 155 BP-100-1.01 - Drug Profile 158 rebastinib tosylate - Drug Profile 160 nivolumab - Drug Profile 162 MRX-34 - Drug Profile 166 ilorasertib - Drug Profile 168 Vaccine to Target WT1 for Oncology - Drug Profile 170 OPB-51602 - Drug Profile 171 CWP-291 - Drug Profile 173 P-2745 - Drug Profile 175 selinexor - Drug Profile 176 CPI-0610 - Drug Profile 179 ABL-001 - Drug Profile 180 Vaccine for Hematological Malignancies - Drug Profile 181 inecalcitol - Drug Profile 182 SL-501 - Drug Profile 184 ON-044580 - Drug Profile 185 SyB-0702 - Drug Profile 186 MRx-102 - Drug Profile 187 Mab81.2 - Drug Profile 189 BGB-324 - Drug Profile 191 D12PGJ-3 - Drug Profile 192 SUNK-706 - Drug Profile 193 Small Molecule to Inhibit ADAR1 for Chronic Myeloid Leukemia - Drug Profile 194 interferon alfa-2b - Drug Profile 195 D-824 - Drug Profile 196 ON-012380 - Drug Profile 197 SNG-1153 - Drug Profile 198 MJ-05 - Drug Profile 199 PF-114 - Drug Profile 200 DP-00605 - Drug Profile 201 Small Molecules to Inhibit Abl Tyrosine Kinase for CML - Drug Profile 202 TR-120 - Drug Profile 203 NOV-120501 - Drug Profile 204 Small Molecule to Inhibit BCR-Abl/LYN for Chronic Myelocytic Leukemia - Drug Profile 205 Small Molecules to Inhibit BRCA2/Rad51 Interaction for Cancer - Drug Profile 206 Small Molecules to Inhibit Bcr-Abl for CML and Pancreatic Cancer - Drug Profile 207 Small Molecules to Inhibit BCR-ABL for Cancer - Drug Profile 208 interferon alfa-2a - Drug Profile 209 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Recent Pipeline Updates 210 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects 290 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Discontinued Products 291 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Product Development Milestones 292 Featured News & Press Releases 292 Appendix 303 Methodology 303 Coverage 303 Secondary Research 303 Primary Research 303 Expert Panel Validation 303 Contact Us 304 Disclaimer 304
List of Tables Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), H2 2014 15 Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Comparative Analysis, H2 2014 16 Number of Products under Development by Companies, H2 2014 18 Number of Products under Development by Companies, H2 2014 (Contd..1) 19 Number of Products under Development by Companies, H2 2014 (Contd..2) 20 Number of Products under Investigation by Universities/Institutes, H2 2014 22 Comparative Analysis by Late Stage Development, H2 2014 23 Comparative Analysis by Clinical Stage Development, H2 2014 24 Comparative Analysis by Early Stage Development, H2 2014 25 Comparative Analysis by Unknown Stage Development, H2 2014 26 Products under Development by Companies, H2 2014 27 Products under Development by Companies, H2 2014 (Contd..1) 28 Products under Development by Companies, H2 2014 (Contd..2) 29 Products under Investigation by Universities/Institutes, H2 2014 30 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Bristol-Myers Squibb Company, H2 2014 31 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Boehringer Ingelheim GmbH, H2 2014 32 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by GlaxoSmithKline plc, H2 2014 33 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Gamida Cell Ltd., H2 2014 34 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by BioLineRx, Ltd., H2 2014 35 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Piramal Enterprises Limited, H2 2014 36 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Nanotherapeutics, Inc., H2 2014 37 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Bio-Path Holdings, Inc., H2 2014 38 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Novartis AG, H2 2014 39 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2014 40 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Pfizer Inc., H2 2014 41 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Celgene Corporation, H2 2014 42 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Incyte Corporation, H2 2014 43 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Ariad Pharmaceuticals, Inc., H2 2014 44 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by JW Pharmaceutical Corporation, H2 2014 45 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Ilyang Pharmaceutical Co., Ltd, H2 2014 46 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2014 47 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Threshold Pharmaceuticals, Inc., H2 2014 48 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Synta Pharmaceuticals Corp., H2 2014 49 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Natco Pharma Limited, H2 2014 50 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Hybrigenics S.A., H2 2014 51 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by SymBio Pharmaceuticals Limited, H2 2014 52 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Nerviano Medical Sciences, H2 2014 53 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Constellation Pharmaceuticals, Inc., H2 2014 54 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Deciphera Pharmaceuticals, LLC, H2 2014 55 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Stemline Therapeutics, Inc., H2 2014 56 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Onconova Therapeutics, Inc., H2 2014 57 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Mirna Therapeutics, Inc., H2 2014 58 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by KaloBios Pharmaceuticals, Inc, H2 2014 59 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by AB Science, H2 2014 60 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Aprea AB, H2 2014 61 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by PharmaEssentia Corporation, H2 2014 62 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Targa Therapeutics Corp., H2 2014 63 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Otsuka Holdings Co., Ltd., H2 2014 64 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Shenogen Pharma Group Ltd., H2 2014 65 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by BerGenBio AS, H2 2014 66 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Karyopharm Therapeutics, Inc., H2 2014 67 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Cantargia AB, H2 2014 68 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by AbbVie Inc., H2 2014 69 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Biogenomics Limited, H2 2014 70 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Galileo Research s.r.l., H2 2014 71 Assessment by Monotherapy Products, H2 2014 72 Number of Products by Stage and Target, H2 2014 75 Number of Products by Stage and Mechanism of Action, H2 2014 79 Number of Products by Stage and Route of Administration, H2 2014 82 Number of Products by Stage and Molecule Type, H2 2014 85 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Therapeutics - Recent Pipeline Updates, H2 2014 215 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects, H2 2014 295 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Discontinued Products, H2 2014 296
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
